Singapore markets closed

Straits Times Index
3,280.10
-7.65(-0.23%)
Nikkei
37,934.76
+306.28(+0.81%)
Hang Seng
17,651.15
+366.61(+2.12%)
FTSE 100
8,139.83
+60.97(+0.75%)
Bitcoin USD
62,941.46
-565.36(-0.89%)
CMC Crypto 200
1,304.48
-92.06(-6.59%)

Roivant Sciences Ltd. (ROIV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

11.03

+0.15

(+1.38%)

At close: 04:00PM EDT

10.63

-0.40

(-3.63%)

After hours:

05:06PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
PR Newswire
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Simply Wall St.
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...